You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Pediatric Growth Hormone Deficiency: Examining Once-Weekly Treatments to Improve Adherence and Outcomes

  • Authors: Lawrence A. Silverman, MD; Bradley S. Miller, MD, PhD; Mitchell Geffner, MD
  • CME / CE Released: 9/29/2022
  • Valid for credit through: 9/29/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    IPCE - 0.5 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for pediatric endocrinologists and advanced practice providers who are involved in the care and treatment of patients with pediatric GHD.

The goal of this activity is that learners will be better able to examine new and emerging growth hormone (GH) treatments for managing GHD with a team.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Gaps in care of pediatric patients with GHD linked to once-daily treatment options 
    • New/emerging once-weekly treatment options for managing pediatric GHD
    • Strategies of care team members for improving adherence to care in pediatric patients with GHD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Lawrence A. Silverman, MD

    Division Chief, Pediatric Endocrinology
    Goryeb Children's Hospital
    Atlantic Health System
    Morristown, New Jersey

    Disclosures

    Lawrence A. Silverman, MD, has the following relevant financial relationships:
    Consultant or advisor for: Ascendis Pharma; Enteris; Novo Nordisk; OPKO Health; Pfizer; Tolmar
    Speaker or member of speakers bureau for: Pfizer
    Research funding from: Ascendis Pharma; Lumos; Novo Nordisk; Pfizer
    Owns stock (publicly traded) in: Johnson and Johnson

Faculty

  • Bradley S. Miller, MD, PhD

    Professor
    Division Director, Pediatric Endocrinology
    University of Minnesota Medical School
    MHealth Fairview Masonic
    Children's Hospital
    Minneapolis, Minnesota

    Disclosures

    Bradley S. Miller, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Ascendis Pharma; BioMarin; Bristol Myers Squibb; EMD Serono; Endo Pharmaceuticals; Novo Nordisk; Orchard Therapeutics; Pfizer; Tolmar; Vertice
    Research funding from: AbbVie; Aeterna Zentaris; Alexion; Amgen; Amicus; Lumos Pharma; Lysogene; Novo Nordisk; OPKO Health; Pfizer; Prevail Therapeutics; Sangamo Therapeutics

  • Mitchell Geffner, MD

    Ron Burkle Chair in the Center for Endocrinology, Diabetes and Metabolism
    Professor of Pediatrics, Keck School of Medicine of USC
    The Saban Research Institute at Children's Hospital Los Angeles
    Los Angeles, California

    Disclosures

    Mitchell Geffner, MD, has the following relevant financial relationships:
    Consultant or advisor for: Adrenas; Eton Pharmaceuticals; Ferring; Neurocrine Biosciences; Novo Nordisk; Nutritional Growth Solutions; Pfizer
    Research funding from: Novo Nordisk

Editor

  • Asha P. Gupta, PharmD, RPh

    Associate Medical Education Director, Medscape, LLC 

    Disclosures

    Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.  

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and the Pediatric Endocrine Society (PES).
Pediatric Endocrine Society

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Pediatric Growth Hormone Deficiency: Examining Once-Weekly Treatments to Improve Adherence and Outcomes

Authors: Lawrence A. Silverman, MD; Bradley S. Miller, MD, PhD; Mitchell Geffner, MDFaculty and Disclosures

CME / CE Released: 9/29/2022

Valid for credit through: 9/29/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to examine new and emerging growth hormone (GH) treatments for managing GHD with a team.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print